SURMOUNT Trial Data, What Researchers Are Working From The pivotal SURMOUNT-1 trial (Jastreboff et al., NEJM 2022, NCT04184622) enrolled 2,539 adults with obesity (no type 2 diabetes) over 72 weeks
Yes, most patients can continue their regular tirzepatide dosing schedule with mild injection site reactions, but should inject into a different site away from the irritated area
During the consultation, we will review the patients medical history, including any underlying medical conditions, medications, and lifestyle factors, to determine whether GLP-1 is a suitable treatment option We will explain how the medication works, its potential benefits and risks, and any lifestyle changes that will be necessary to optimize the treatment outcomes
My top pick is the High Fiber Bowl, thanks to its 14 grams of fiber and 46 g of protein
However many ads, featuring pounds and US dollars, also appear in Australians social media feeds
No separate reconstitution is required